ArticleEuropean journal of pediatrics2025
Low to moderate-dose off-label use of second-generation antipsychotics seems to be safe in the light of cardiac adverse effects in child psychiatric patients.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Second-generation antipsychotics (SGAs) may increase the risk for ventricular arrhythmias by prolonging the rate-corrected QT interval (QTc) on an electrocardiogram (ECG). This prospective study aimed to examine QTc changes in child psychiatric patients during the implementation of an SGA monitoring protocol. QTc was calculated using both Bazett's (QTcB) and Fridericia's (QTcF) formula and categorised as normal (≤ 450 ms), borderline (> 450, < 470 ms), prolonged (≥ 470, < 500 ms), or significantly prolonged (≥ 500 ms). The study patients (n = 55, 76% males, median age 9.9 years) were followed for a median of 9 months. In all of them SGA (risperidone, aripiprazole, quetiapine) treatment was off-label. The median olanzapine equivalent dose was 2.0 mg. Concurrent ADHD medication was used by 40%. A baseline (BL) ECG was available for 78%. A BL and at least one follow-up ECG existed for 75%. The mean change in QTcB was 18.1 ms (p < 0.001) and in QTcF 17.2 ms (p < 0.001). The QTcB change was significantly greater in females (31.7 ms vs 13.2 ms, p = 0.046). During the follow-up, 11% had borderline (n = 5) or significant (n = 1) QTcB prolongation. In 5/6, the prolongation appeared after a change in psychotropic medication. No arrhythmias were detected.
conclusionLow to moderate-dose SGA treatment in children seems to be safe in the light of cardiac adverse effects. However, individual risk assessments and systematic ECG monitoring are necessary. Particular attention should be paid to medication changes and female patients. WHAT IS KNOWN: • Second-generation antipsychotics (SGAs) may prolong the rate-corrected QT interval (QTc) and increase the risk for ventricular arrhythmias. • The risk seems to be low in healthy children, but data on long-term treatment and patients with risk factors are scarce. WHAT IS NEW: • In this clinical sample of 55 children using SGAs, QTc prolongation was seen after changes in psychotropic medication. • Individual cardiac risk assessment including family history and monitoring of SGA treatments is vital. Attention should be paid to medication changes and female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.